{"id":"NCT01974440","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-31","primaryCompletion":"2022-05-30","completion":"2023-06-21","firstPosted":"2013-11-01","resultsPosted":"2023-04-14","lastUpdate":"2025-05-25"},"enrollment":403,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"Bendamustine","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"PCI-32765 (Ibrutinib)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment Arm A","type":"PLACEBO_COMPARATOR"},{"label":"Treatment Arm B","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.","primaryOutcome":{"measure":"Primary Analysis: Progression Free Survival (PFS): Stratified Analysis","timeFrame":"Up to 8 years","effectByArm":[{"arm":"Placebo + Chemoimmunotherapy (CIT)","deltaMin":23.75,"sd":null},{"arm":"Ibrutinib + CIT","deltaMin":40.51,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0922"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":135,"countries":["United States","Argentina","Australia","Belgium","Brazil","China","France","Germany","Israel","Japan","Poland","Puerto Rico","Russia","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37722354"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":199},"commonTop":["Nausea","Diarrhoea","Neutropenia","Fatigue","Pyrexia"]}}